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Abstract
Much more specialists are nowadays aligning themselves on the view according to which 
the prevalence of cardiovascular disease will reach epidemic levels in the near future 
due to the increase of hypertension, diabetes and obesity. Most epidemiological studies 
indicate that we are confronted with a multiplication of risk factors, with an empha-
sis on their genetic conditioning as well as an acceleration of the effects generated by 
non-genetic factors. According to WHO recommendations, the appropriate methods of 
reducing the cardiovascular risk are those that combine health policies with efficient edu-
cation measures. Long-term results of these measures aim to decrease the incidence of 
complications and associated costs with their treatment at the same time with increasing 
the quality of life. Approximately 50% of deaths from heart disease could be prevented 
through sustained action on the main cause—hypertension—and by treating risk factors, 
primarily hyperlipidemia and elevated body weight. Atherosclerotic disease requires a 
rigorous approach because identifying predisposing risk factors with proven implica-
tions in the initiation and progression of this disease, as well as modulation of those with 
protective role, can have a significant impact in finding an appropriate treatment in order 
to improve cardiovascular diseases and their consequences.
Keywords: hypertension, diabetes, obesity, atherosclerosis, metabolic syndrome
1. Introduction
Significant research has suggested that vascular segments that have fingerprints of the 
atherosclerotic lesions (endothelial dysfunctions, macrophage activation, cellular proliferation 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
and thrombosis) respond differently on medication, starting from the idea that we can accept 
as a initial point either inflammation or normal lipid profile perturbation [1, 2]. Therapeutic 
approach of the atherogenic dyslipidemia imposes the correlation with proatherogenic 
individual tendencies in order to correct the further risks. Atherosclerosis must be seen as 
a continuous process that starts from small endothelial dysfunctions and leads to important 
alterations of the vascular wall [3, 4]. The use of pharmacotherapeutic agents must be done 
in a tight correlation with the local pathophysiology, evaluating not only the risk factors but 
also the dynamic knowledge and clinical manifestations of this global disease [5, 6]. Although 
there are certain atherogenic risk factors considered causal agents for atherosclerosis, this 
disease can appear and evolve in their absence. Thus, there have been revealed atherosclerotic 
plaques in patients deceased from ischemic cardiomyopathy and especially from myocardial 
infarction, regardless of the blood pressure values, or the cholesterol and triglycerides values, 
and the presence or absence of smoking [7].
2. Main body
Myocardial infarction, stroke and venous thromboembolism represent the most important 
causes of death among female and men. Coronary heart disease, due to atherosclerosis, is a 
cause of myocardial infarction and is the first cause of death in women and men worldwide 
[7]. Strokes by venous or arterial thrombosis are more frequently in menopausal woman, 
whereas the stroke with cerebral hemorrhage, even if is less frequent, appears in young 
female and is caused by a cerebral vascular anomaly. Venous thrombosis includes superficial 
thrombosis that are autolimitated and deep thrombosis, most frequently at the level of pop-
liteal and femoral vein. In approximately 10% of cases, a part of the thrombus or the entire 
thrombus can detach and determine pulmonary embolism [8].
Cardiovascular disease appears in coronary arteries when the atherosclerotic lesions evolve 
from an initial accumulation of isolated foam cells in the arterial intima to fatty streaks, fol-
lowed by the accumulation of cholesterol deposits and atheroma formation. Once the atheroma 
is formed, the collagen from the fibrous cap stabilizes the plaque and prevents its rupture. 
But, matrix metalloproteinases, which are produced by the inflammatory cells from the lesion 
level, may degrade the collagen, and in case of a rupture of the fibrous cap, the resulted thro­
mbus can block the affected coronary artery [9].
Cardiovascular disease may have their origin in the intrauterine life, but also a low birth 
weight and an extremely rich diet increase the risk of obesity and a specific metabolic syn-
drome in adults. Cardiovascular disease incidence and mortality are very low in reproductive 
age women, but it increases with age [8].
Estradiol (E2) reduces the development of the early atherosclerotic lesions, in some measure, 
by its effects on the lipid metabolism, with a reduction of the lipid deposits from the intima. 
On the other hand, at the level of the already made atheroma, the estrogens increase the 
matrix metalloproteinases expression, which can lead to the disruption of the fibrous cap 
and the rupture of the plaque. In this case, a turbulent blood flow is produced; the estradiol 
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has thrombogenic properties and leads to clot formation that may obstruct the arterial 
lumen [10]. Therefore, through various mechanisms, the estrogens inhibit the early develop-
ment of the atherosclerosis but at the same time increase the risk of complications once the 
atherosclerosis has been installed. Atherosclerotic lesions from the carotids and cerebral ves-
sels may be affected by similar mechanisms; thus, in comparison with men, women are rela-
tively protected by the thrombotic stroke before menopause, and any hormonal impact leads 
to changes in the status of the coagulation, anticoagulation and thrombotic factors [11].
World Health Organization conducted numerous studies regarding the mortality due to 
myocardial infarction, stroke and venous thromboembolism in many countries across the 
world [12]. Mortality by myocardial infarction in women increases exponentially with age. 
It is twice as high in American population as in the West Pacific population. The mortality 
rate of this condition is smaller in reproductive aged people, being 1–7 in 100,000 women 
aged 35–44 years/year. Reproductive aged women have 3–5 times smaller mortality rates 
than men, becoming similar over the age of 65 years. Consequently, age has a major influ-
ence because the number and the severity of the lesions increase with age; for this reason, the 
prevention of the atherosclerosis progression is very important, even in the seventh or eighth 
decade of life [13]. Atherosclerosis is not symptomatic until midlife or later, when the arterial 
lesions determine organ injury. However, cardiovascular signaling markers were frequently 
identified in children in the last few years. Anatomopathological examination of coronary 
arteries sampled from children who died in accidents showed fatty streaks and fibrous caps, 
in smoking, high blood pressure, obese or dyslipidemic subjects. Therefore, it is mandatory 
to identify the risk factors at an early age in order to prevent the premature appearance of 
myocardial infarction [14, 15]. Epidemiological studies revealed an increased incidence of 
myocardial infarction approximately five times higher in individuals between the ages of 40 
and 60 years [16].
Hormonal contraceptives, pregnancy and polycystic ovary syndrome in young women and 
menopause in older women are directly linked with cardiovascular diseases [17]. The use of 
combined hormonal contraceptives has minor effects in cardiovascular disease, given the low 
incidence of myocardial infarction, stroke and venous thromboembolism in young women. 
However, women who already have risk factors or cardiovascular diseases should take into 
consideration alternative contraceptive methods. In pregnant women, cardiovascular diseases 
are rare; even in West countries they determine a significant proportion of maternal mortality 
compared to the substantial decrease of obstetrical mortality. The frequency of venous throm-
boembolism is 15 in 10,000 in pregnancy and post­partum period [18]. In older woman, it 
seems that menopause determines a higher risk of myocardial infarction, even if the results of 
numerous studies show a significant risk of heterogeneity. It is known that estrogen reduces 
the risk of developing atherosclerosis in premenopausal women, whereas in post-menopause, 
in women with atherosclerotic disease, the estrogen increases the risk of myocardial disease 
by its effects over the plaque stability and clot forming. The recent study results indicate that 
hormonal treatment in menopause does not always improve the risk of myocardial infarction, 
stroke or other vascular diseases. Thus, cardiovascular disease prevention should be based on 
diet and sport, small doses of platelet antiaggregant and treatment of high blood pressure, 
hyperglycemia and hyperlipidemia [19, 20].
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The atherosclerosis complications are unusual in premenopausal women, with the excep-
tion of the ones predisposed to diabetes mellitus, hyperlipidemia or high blood pressure. 
The incidence of diseases related to atherosclerosis increases in menopause, probably being 
connected to the disappearance of the hormonal protection [16]. Some data demonstrated 
that estrogen replacement therapy has a favorable effect over the risk, increasing HDL and 
decreasing LDL levels [21]. The use of steroid hormonal contraceptives increases two to three 
times coronary atherosclerosis risk, mainly in smoking female over 35 years [22].
In the last few years, the criteria for metabolic syndrome have been reviewed: abdominal 
obesity, increased serum cholesterol, high blood pressure, insulin resistance with or without 
impaired glucose tolerance, pro­inflammatory status, a high level of C­reactive protein and 
a prothrombotic status with a high plasmatic fibrinogen and coagulation factors level [23].
Morphological and experimental studies have demonstrated connections between hyperlip-
idemia, especially hypercholesterolemia, and atherosclerosis, both in women and in men. The 
content of the atheroma plaque, which is made of cholesterol and cholesterol esters, the struc-
ture of the foam cells and the experimental production of atherosclerosis by a high-fat diet, 
has been initial arguments for the implication of lipids in atherosclerosis genesis. Cholesterol 
and triglycerides are the lipids with the highest impact for atherosclerosis and ischemic car-
diomyopathy. Prospective studies showed that patients with a plasmatic cholesterol level 
over 260 mg% have a three or four times higher incidence of atherosclerosis than the patients 
with a level under 200 mg% [24]. From the total cholesterol, the major component that is 
associated with a high risk is LDL­cholesterol that has an essential physiological role in sup-
plying the cholesterol to the peripheral tissue [25]. In opposition, HDL­cholesterol has the 
role of uptaking the cholesterol from the forming atheroma or from those already formed 
and transport it to the liver. Beside the ability of removing the cholesterol from the cellu-
lar level, HDL­cholesterol has anti­inflammatory, antioxidant and antithrombotic properties 
that contribute to the improvement of the endothelial function and atherosclerosis inhibition. 
Therefore, as the HDL­cholesterol level is higher, the risk of developing atherosclerosis low-
ers [26, 27]. In different experimental models, carbohydrate restriction proved to be efficient 
in the decrease of the plasmatic triglycerides, increase of HDL­cholesterol and modifying 
the repartition of the LDL­cholesterol [28]. The physical exercises and moderate consume 
of ethanol increase the HDL­cholesterol level, whereas the obesity and smoking decrease it. 
High cholesterol diets or saturated fats, like the ones from the butter, animal fats and yolk, 
increase the level of the plasmatic cholesterol, whereas the diets poor in cholesterol and poly-
unsaturated fats decrease it. Omega­3 fatty acids, found in fish oil, are probably beneficial, 
whereas the unsaturated fats produced by the artificial hydrogenation of the vegetable poly-
unsaturated fats and used in alimentation may influence negatively the cholesterol profiles, 
conducting to atherosclerosis. Beneficial effects of the omega fatty acids have been observed 
in the Northern countries, where the consumption of a large quantity of fish determined a 
decrease of the cardiovascular disease. If the cholesterol value cannot be diminished by diet, 
we can use drugs named statins that reduce the indirect circulating cholesterol by inhibiting 
the HMGCoA­reductase, a key enzyme necessary for the biosynthesis of the cholesterol in 
the liver [16, 29, 30]. From the existing statins on the market, studies showed the efficacy in 
cardiovascular disease prevention for Atorvastatin and Rosuvastatin [31].
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Early coronary artery disease appears usually in patients with medical history of hypercho-
lesterolemia. Numerous laboratory tests showed significantly higher levels of cholesterol and 
lower levels of HDL­cholesterol (especially of HDL2) in patients under 40 years old with 
coronary artery disease (men or women) compared to patients over 60 years old to whom the 
disease could be noticed [32].
The screening involves dosing cholesterol and LDL­cholesterol levels, and it is recommended 
to all the adults, especially to young people with a familial history of early ischemic cardio-
myopathy. The actual dyslipidemia guideline highlights the importance of maintaining the 
LDL­cholesterol value within normal limits and reporting the cardiovascular disease to this 
value [33].
Polycystic ovary syndrome should be seen as a metabolic disease, with a high risk in devel-
oping diabetes mellitus type 2 and different cardiovascular disease [34]. If the glucose value 
is between 110 and 120 mg/dl, it is mandatory to perform the oral glucose tolerance test 
that allows us to precocious discover the diabetes mellitus and remove the complications. 
According to an international consent about the diagnostic criteria (The Rotterdam ESHRE/
ASRM­Sponsored PCOS Consensus Workshop Group, 2004), this syndrome is characterized 
by oligomenorrhea/amenorrhea, hyperandrogenism and polycystic ovaries. In addition, this 
syndrome is frequently associated with obesity and insulin resistance. Although women with 
this syndrome require medical assistance for unregulated menstrual cycles, hirsutism and 
infertility, it should not neglect the high risk of developing cardiovascular disease; therefore, 
clinician attention should be directed also to long­term prevention over these diseases [35].
Recent clinical studies regarding this syndrome established the existence of some metabolic 
risk factors in these women. The intermediary results include endothelial dysfunction, plate-
let dysfunction, increased number of leukocytes or high levels of C-reactive protein, coronary 
calcifications and the increase of the intima­media thickness at the carotid level. A study con-
ducted on 161 patients with polycystic ovary syndrome also established frequent alterations 
in the metabolic syndrome parameters [36]. Regarding intermediate results, 33 women aged 
between 40 and 59 years, with histological confirmed syndrome, have been followed up to 
2–3 decades concluding that they developed obesity, high prevalence of diabetes mellitus and 
high blood pressure, compared with a same aged group [37].
Concerning the cardiovascular events, limited studies on females with polycystic ovary syn-
drome provided contradictory results, even if it has been established a certain correlation 
with a metabolic syndrome. We must highlight the fact that most studies are retrospective, 
on a small number of patients, on a short follow-up and a lot of questions regarding the 
control groups [38, 39]. Large prospective cohort studies, like Framingham or Nurses Health 
Study, focused over results about cardiovascular disease or cancers, could not identify hyper-
androgenism and anovulation as a separate risk phenotype. If we talk about American popu-
lation, they can calculate their death risk by cardiovascular disease using Framingham score. 
In Europe, we should take into consideration SCORE risk charts (Systematic Coronary Risk 
Evaluation Project). This allows each person to simply calculate his death risk by cardiovas-
cular disease in the next 10 years. It has the advantage that is very easy to use and all we need 
to know is gender, age, smoking status, blood pressure and cholesterol level. It can be used by 
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anybody and brings precious individualized information based on which it can be prescribed 
a treatment. A retrospective study from Great Britain, which included 786 women diagnosed 
with polycystic ovary syndrome between 1930 and 1979, could not establish the increase of 
the cardiovascular disease [40] or the morbidity [41] in these patients.
Cardiovascular disease is less frequent in women in reproductive age. First report regarding 
the cardiovascular disease as a secondary effect of the contraception took place in 1961, short 
after the discovery of the combined oral contraceptives [42]. Starting from 1960, estrogen and 
progesterone doses from contraceptive pills have been dramatically reduced and were cre-
ated new progestatives that are theoretically safer. Substantial data regarding the effects of 
the combined oral contraceptives over the cardiovascular disease exist, but there are less evi-
dence for the contraceptive pills that contain only progesterone [43].
High blood pressure is a condition characterized by an increase of the systolic value over 140 
mmHg and of the diastolic value over 90 mmHg, being a major risk factor for atherosclerosis 
at all ages, females being less affected [16]. Prothrombotic condition and Lp(a) are two risk 
factors correlated with the development and the progression of the organic damage in high 
blood pressure and also in the evolution of the atherosclerotic process [44]. Antihypertensive 
drugs reduce the incidence of atherosclerosis-associated diseases, such as strokes and isch-
emic heart disease [45]. High blood pressure is a risk factor common in old people compared 
to young people with a myocardial infarction, frequently found in females [46]. Mechanisms 
by which the high blood pressure accelerates the atherogenesis include: the direct lesion of 
the endothelial cells from the susceptible zones from the mechanic stress exercised over the 
vascular lumen, the alteration of the endothelial permeability with the increase of the lyso-
somal enzymes activity, the gradual thickening of the arterial intima caused by the prolifera-
tion of the smooth muscle fiber and connective tissue components [16].
Another extremely important risk factor involved in women atherosclerosis is heredity. 
Variable damage of the genes together with the environmental factors determines a differ-
ent atherogenic predisposition among the population. It has not been identified yet a genetic 
marker for atherosclerosis, but it seems that the genetic predisposed subjects for this degen-
erative disease are more vulnerable if associated with risk factors. Familial predisposition to 
atherosclerosis and ischemic heart disease is most probably polygenic [16] and normally is 
associated with other risk factors, like high blood pressure and diabetes mellitus. Familial 
risk for ischemic cardiomyopathy is extremely high in some dyslipidemia: familial hypercho-
lesterolemia, polygenic hypercholesterolemia and polygenic hypoalphalipoproteinemia [47].
Numerous proatherogenic factors have been discovered in various studies. Apolipoprotein 
E, with its three principal variants (E2, E3, E4), is a good example of genetic polymorphism 
involved in the atherosclerotic process [48]. In different populations, it was demonstrated 
that Apo E polymorphism is a major determinant for coronary disease. The risk of myocar-
dial infarction is smaller in patients with epsilon 2–E2 allele than the patients with epsilon 
4–E4 allele [49]. A decreased frequency of epsilon 4 allele has been found in the Northern 
countries of Europe, whereas this increases in the Southern Europe, like the cardiovascular 
disease mortality rate. In addition, a strong relationship between the medical history and the 
epsilon 4 Apo E distribution was established. Despite normal LDL, HDL and total cholesterol 
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values, Apo E polymorphism has been associated with negative prognostic, which raised the 
hypothesis that epsilon 4 allele represents a determinant factor for accelerated atherosclerosis 
in young people with myocardial infarction, by the modulation of other risk factors [50].
Decreased arterial compliance has a high predictive value for cardiovascular events, so its 
evaluation becomes an important objective in investigating the arterial function [51]. Various 
epidemiological and clinical studies brought arguments for a genetic component that is 
involved in the modulation of the arterial wall properties, unrelated with other risk factors 
[52]. An important number of genes that might affect the structure and role of the arterial wall 
exist (genes implied in different signaling paths and in modulating the extracellular matrix), 
and their identification is extremely important, offering on the one hand new biomarkers that 
are useful in evaluating the arterial compliance, and on the other hand new therapeutic tar-
gets in order to decrease the vascular rigidity [53, 54]. Currently, the arteriography allows the 
noninvasive quantification of vascular rigidity and long­term monitoring in cardiovascular 
rehabilitation programs.
Recent studies have shown that smoking is the most important adjustable risk factor in women 
and men under 40 years old with acute coronary syndrome, being observed in mostly equal 
parts in those with normal coronary arteries and in those with lesions on one or more coro-
nary arteries [55]. Smoking is involved in endothelial dysfunction by reducing the production 
of the nitric oxide, causing the coronary spasm [37]. Smoking one pack a day or more than 
one pack for years increases the ischemic cardiac disease mortality rate up to 200%. Smoking 
cessation considerably reduces the risk of developing the disease [16, 56].
Diabetes mellitus induces hypercholesterolemia and in consequence an increase in predispo-
sition for atherosclerosis in both male and female. The incidence of the myocardial infarction 
is two times higher at patients with diabetes mellitus compared to patients without diabe-
tes. Also they have a higher risk for strokes and it increases almost 100 times the risk of the 
gangrene on the inferior limb, induced by atherosclerosis, being most often discovered at 
smoker patients with diabetes [16]. This disease affects the elastic properties of the arterial 
wall, no matter the presence of other risk factors or intimal damage in patients with peripheral 
vascular disease [57]. Acute hypoglycemia causes important physiological changes, affecting 
cardiovascular system and some hematological parameters, mainly as a consequence of the 
sympatho­adrenergic activation. In healthy adults, cardiovascular effects are transitory and 
do not have severe consequences, but can become pathological in patients with diabetes that 
already have endothelial dysfunction. The risk of localized tissue ischemia may be increased 
by acute hemodynamic and hematologic alterations; also, major vascular events like myo-
cardial or cerebral ischemia may be precipitated by acute hypoglycemia [58]. Clinical and 
experimental studies sustain the idea that insulin resistance syndrome and increased levels of 
circulating insulin are involved in cardiac ischemic disease [59].
High blood pressure and diabetes mellitus are risk factors associated most of the time in patients 
with cardiovascular diseases. Impaired glucose tolerance is accompanied by an increase in the 
thickness and the rigidity of great vessels, which determines high blood pressure, macro-
vascular complications and decreased renal function [60]. Chronic hypertension and diabe-
tes produce physiopathological changes both in great vessels and in  microvascularization.
Overview of Some Risk Factors in Cardiovascular Disease
http://dx.doi.org/10.5772/intechopen.69039
43
The increase of the arterial rigidity leads to increased systolic pressure and pulse pressure that 
conducts to a fall in the coronary perfusion. The remodeling of the resistance arteries and the 
capillary rarefaction causes the growth of the peripheral resistance, with high blood pressure 
and the amplification of the negative hemodynamic effects of the reduced arterial compliance; 
therefore, therapeutic interventions that must stop these vascular changes should have the 
aim to increase the central systolic pressure and the increase of the vascular bed perfusion 
[61, 62].
Patients with homocystinuria, which is a congenital metabolic disorder, characterized by 
elevated levels of circulating homocysteine (> 100 μmol/L) and urinary homocysteine, pres-
ents an early vascular injury [63]. Clinical and epidemiological studies revealed a connection 
between the serum levels of homocysteine and peripheral vascular disease, coronary artery 
disease, stroke, venous thrombosis, meaning that a high concentration of homocysteine is 
associated with the progression of the atherosclerosis [64]. Also, high concentrations of homo-
cysteine imperil the endothelial function, increase the oxidative stress, affect the methylation 
reactions and alter the protein structures [63]. Hyperhomocysteinemia can be caused by the 
reduced absorption of the folic acid and B type vitamins and, in consequence, recent data 
suggest that folic acid and B6 vitamin ingestion, together with a proper diet, could reduce the 
incidence of cardiovascular disease, but this remains to be established in further studies [16]. 
An increase of homocysteine concentration is correlated with a 10% risk of coronary disease. 
The increase of homocysteine up to 5 micromol/L carries a 41% higher risk, similar to a choles-
terol increase with 0.52 micromol/L (20 mg/L). Smoking and high blood pressure amplify the 
atherogenic action of high homocysteine levels. The association between hyperhomocysteine 
and factor V Leiden increases three to six times the thrombosis risk [65, 66].
A particular interest is conferred to the infectious etiology of atherosclerosis. Viral infections 
(herpes viruses, HIV-1), Mycoplasma or Chlamydia can affect the endothelial cell function and 
thus an increased adherence of the leukocytes and thrombocytes at the injured vascular sec-
tion [67, 68]. Numerous studies showed that atherosclerosis can be the consequence of the 
adaptive immunity due to microbial HSP-60 (Heat Shock Protein-60). Stress factors induce 
the growth of the HSP expression on the endothelial cells and the cross-reactivity between 
the antibodies and the microbial HSP that lead to autoimmune reaction and accelerated ath-
erosclerosis. The association between the infectious syndrome and coronary disease has been 
reported in many studies [69].
It has been issued the hypothesis that the infection of the vascular wall with pathogen agents 
like Chlamydia pneumoniae or cytomegalovirus (CMV) contributes to the appearance of athero-
sclerosis by insertion of new antigens in the vessel wall [70, 71]. C. pneumoniae was evidenced 
by direct immunofluorescence on endarterectomy pieces or by antibodies anti­C. pneumoniae 
in plasma. Chlamydia pneumonia and CMV were absent in non-atherosclerotic vessels. The use 
of antibiotics in certain infections limits the atherosclerotic process [72].
At vascular wall level where atherosclerosis appears, there is a particular accumulation of 
mononuclear cells, CD4+ and CD8+ lymphocytes [73]. Endothelial cells, macrophages and 
dendritic cells have a role of antigen­presenting cells [72]. Infectious agents can infect macro-
phages and persist for a long time at their level, producing proinflammatory cytokine (INF­γ, 
Recent Trends in Cardiovascular Risks44
TNF­α, IL­1, IL­6, IL­8), metalloproteinase and integrins [74, 75]. It is important to mention 
the antigenic mimetism between oxidized LDL and Streptococcus pneumoniae; subsequently, 
the vaccination with pneumococcal antigen induces an immune response against oxidized 
LDL that might immunomodulate the atherosclerosis process [76].
Other factors that are hard to evaluate include the physical effort, type A of personality (char-
acterized by a stressed lifestyle), obesity; they determine high blood pressure, diabetes mel-
litus, hypertriglyceridemia and increase of LDL­cholesterol [16]. Regularly physical activity 
induces the increase of HDL­cholesterol, slowing the atherogenesis process and preventing 
ischemic cardiomyopathy. Physical and emotional stress and anxiety seem to be precipitating 
factors for ischemic heart disease and sudden death [77]. In Framingham study, cardiovas-
cular disease incidence was two times higher in obese men and 2.5 times in obese women 
under 50 years old [78]. Adipose tissue considered for a long time just a fat source, seems to 
be a proinflammatory endocrine and paracrine secretion organ. It is recognized as being an 
important source of proinflammatory mediators that can contribute in vascular injury, insulin 
resistance and atherogenesis. So the inflammation of the adipose tissue can be an important 
step in developing numerous manifestations in connection with pathological characteristics 
of metabolic syndrome and may lead to diabetes and atherosclerosis [79, 80]. Defining a rel-
evant obesity phenotype for cardiovascular risk can be done by adipocytokine identification, 
biomarkers that quantify the metabolic activity of the adipose tissue [81]. According to their 
effect, adipocytokines can be classified into proinflammatory adipocytokines, mediators of 
endothelial dysfunction and atherosclerosis that include TNF­α (tumor necrosis factor), IL­6 
(interleukin 6), leptin, plasminogen activator inhibitor (PAI-1), angiotensinogen, resistin and 
C-reactive protein (CRP), and adipocytokines with antiatherosclerotic role represented by 
nitric oxide (NO) and adiponectin [82].
Multiple risk factors cumulate their effects. The presence of two risk factors increases the risk 
almost four times; if there are three risk factors, the rate of myocardial infarction increases 
seven times. Also, the level of exposure at risk factors determines considerable variations in 
the evolution of the atherosclerotic process and this is the reason why and early determination 
through different methods would be extremely useful in the evaluation of the cardiovascular 
risk [83]. Atherosclerosis and its consequences may develop in the absence of any risk factor, 
even in people who have a healthy life and without an apparent genetic predisposition [16].
In accordance with European Society of Cardiology Guidelines on Cardiovascular Disease 
Prevention (2007), the population should follow the next formula: 0 3 140 5 3 0, which suggest 
crucial measurements in keeping the cardiovascular health: without smoking (0), walking 3 
km per day or 30 min of moderate activity (3), systolic pressure less than 140 mmHg (140), 
total cholesterol under 5 mmol/L (5), LDL­cholesterol under 3 mmol/L (3), eviction of obesity 
and diabetes (0) [84]. Actual guides recommend performing moderate physical activity mini-
mum 30 min per day five times a week [85].
Epidemiologic data show that there are some hemostatic, thrombolytic and inflammation mark-
ers that are potential predictors of the risk for major atherosclerotic events, including myocar-
dial infarction and stroke. These markers are related to fibrinolysis (e.g.: PAI 1—plasminogen 
activator inhibitor 1) or inflammation (CRP—C­reactive protein). PAI­1 plays an important role 
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in cardiovascular diseases, mostly by inhibiting t­PAC (tissue plasminogen activator) [16, 86]. 
Inflammation biomarkers, especially CRP and lipoprotein­associated A2 phospholipase, are 
considered not only as potential risk predictors for stroke but also as prognostic factors [87]. 
CRP is considered to be a new proatherogenic inflammatory adipocytokine. CRP is an acute 
phase reactant, being synthesized mostly by the liver and regulated by circulating levels of IL6, 
IL1 and TNF­α. Recent studies demonstrated that high sensitive CRP is not only an atheroscle-
rotic inflammatory marker but also a disease progression mediator, contributing to the forma-
tion and progression of the atheromatous plaque by promoting inflammation, thrombogenesis 
and modulatory endothelial function [88]. CRP induces the expression of adhesion molecule, 
selectins and MCP1 in endothelial cellular cultures, by increasing secretion of ET1 and IL6, and 
also stimulating angiotensin II action over receptors. By inhibiting NO endothelial secretions, 
CRP diminishes basal production and stimulated production of endothelial NO. CRP effect 
is potentiated by hyperglycemia and diminished by thiazolidinedione, an insulin sensitizer 
agent. CRP may also amplify proinflammatory activity of other adipokines, for example, PAI­1 
intervention in the suppression of fibrinolysis and thrombogenesis by the inhibition of the 
activated plasminogen [89]. Increased plasmatic levels of PAI-1 are directly correlated with the 
cardiovascular risk and type 2 diabetes development. Even if platelets and endothelial cells 
represent a major source of PAI-1, in men, adipose tissue produces, also, PAI-1. Increased plas-
matic levels of PAI­1 are found in obese patients and decrease with lowering weight [90].
Latest advances confirmed the role of Lp­PLA2 in advanced coronary disease evolution, being 
an important linking factor between lipid homeostasis and vascular inflammatory response. 
Selective inhibition of Lp-PLA2 reduces the development of the inner core atheroma and leads 
to plaque stabilization [91]. A lipoprotein is a lipid fraction that looks like an independent risk 
factor for atherosclerosis. It represents a modified LDL­cholesterol that has a characteristic 
protein fragment covalent linked to apo B and named apo(a), with an polymorphism and 
a structural analogy with the plasmatic plasminogen. Also, it has a complex prothrombotic 
action. Thus, Lp(a) seems to make the connection between atherosclerosis and thrombosis, the 
two processes being tightly related in atherosclerosis evolution [16, 92].
Serum amyloid A is an acute phase reactant, like CRP, that has been associated with systemic 
inflammation, related to the atherosclerosis process and used as a predictor for coronary dis-
ease and for cardiovascular prognosis. Levels of serum amyloid A are significantly correlated 
to insulin resistance and obesity in type 2 diabetes patients. Adipose tissue maintains amyloid 
at low levels in normal conditions, but an excess of it seems to stimulate this reactant. Serum 
amyloid A replaces apolipoprotein 1 from HDL­cholesterol, increasing the macrophage bond 
HDL and decreasing the cardioprotective HDL [81].
TNF­α is an inflammatory cytokine, which is released in high levels by obese patients and 
those with an increased insulin resistance, and contributes to the initiation and develop-
ment of the atherosclerotic lesions. TNF­α activates the NF­κB nuclear factor transcription 
that accelerates the experimental atherosclerosis, partly by inducing the adhesion molecular 
expression, MCP-1 and E-selectin, in vascular smooth muscle cells and aortic endothelium. 
TNF­α reduces the bioavailability of nitric oxide in endothelial cells and modifies the endo-
thelial­dependent vasodilatation, promoting its dysfunction; in addition of these effects, it 
might also induce apoptosis in endothelial cells [81].
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Epidemiological research showed an obviously different frequency of atherosclerosis 
between geographic regions. The explanations are related to physicochemical properties of 
the drinking water and the meteorological factors. Oligoelements as calcium, magnesium, 
manganese, lithium, zinc, chrome and fluorine have proven antiatherogenic properties. It is 
known that the chronic absence of some oligoelements from the drinking water, with a con-
secutive decrease of its hardness is accompanied by an increase of the cardiovascular disease 
frequency. The opposite is the plumb excess and mostly the cadmium excess, which charac-
terizes the soft water. Meteorological factors do not seem to be implied in the mechanism of 
the disease development. However, they represent important indicators of a major coronary 
accident occurrence, on an atherosclerotic fond [93].
Socioeconomical factors also increase the atherogen risk among the population: overstrain in 
the work place, physical and intellectual overexertion, sudden and frequent changes in the way 
of life and work, commuting, increased professional and familial responsibilities, conflictual 
states (familial, professional), social unintegration, irrational use of food, sedentary state, 
alcohol and excessive smoking. These situations are usually accompanied by an increased 
level of catecholamines, plasmatic lipids and blood pressure, which involves an intensified 
aggression over heart vessels [94].
An efficient therapeutic strategy presumes not only obtaining regression or retreat of existing 
atheroma but also modulating vascular impact in the beginning. It is important to mention the 
fact that atherosclerosis is one of the most frequent vascular disease in developed countries.
It is well known that the negative effect of high blood pressure over atherosclerosis needs a 
critical level of circulating lipoproteins [95]. However, antihypertensive treatment effects on 
atherosclerotic fond are not sufficiently known. Decoding the complex cellular and molecular 
mechanisms of atherogenesis process might certainly influence the therapeutic choice. Even 
if it has been tried on numerous ways to reduce LDL­cholesterol, there are a whole series of 
cardiovascular disease that cannot be efficiently treated. Starting from some medication that 
is centered over HDL, this promotes some certain antiatherogenic effects: antioxidative, anti­
inflammatory, antithrombosis and endothelial stabilization [96].
Considering atherosclerosis as a disease with inflammatory substrate, in the acute phase HDL 
(that normally is anti­inflammatory) may become proinflammatory. Reactive species of oxy-
gen generate an enzymatic system that can modify phospholipids and sterols by oxidation, 
reducing the HDL­cholesterol protection capacity against the unwanted oxidative changes at 
the molecular level [97].
Some experimental studies suggest that the use of mimetic peptides, such as apolipoprotein 
A-1, is capable of removing the oxidative products from lipoproteins and cellular membranes, 
giving back the normal structure and function of HDL­cholesterol [98]. In order to correct the 
HDL value, we currently use two classes of compounds: fibric acid derivatives and niacin 
derivatives. Dyslipidemia is considered as one of the main atherosclerotic risk factors and 
represents one of the atherogenic therapeutic targets [99].
Modern studies posit the therapy with cardiovascular cells (by exogenous ingestion or by 
an endogenous cellular mobilization) as effective in preventing and treating atherosclerotic 
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lesions. Using bone marrow cells or autolog skeletal myoblasts in the beginning, it could be 
observed the fact that cardiac regeneration is produced through a variable repopulation accom-
panied by adjacent revascularization. Nowadays, the mesenchymal stem cells have large­scale 
utilization because of the immunosuppressant capacity and the ability to locate in the damaged 
tissue areas. The ability of stem cells to form myocardial cells has been studied both in vivo 
and in vitro research [100, 101]. Cardiomyoplasty is already used as a regeneration method of 
the damaged myocardium, using different cellular types [102]. This myocardial reconstructive 
technique, which is under a clinical evaluation and a rigorous immunological monitorization, 
could change the approach of cardiovascular disease therapy in the near future.
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